30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: Amedica

$5.8MM, -4% (U.S. $5.8MM, -4%; ex-U.S. $0.02MM, -4%)

  • Silicon Nitride (SiN) Products $2.7MM, +51%
  • Non-SiN $3.1MM, -27%


  • SiN growth attributed to increased adoption of 2nd-gen Valeo interbody devices
  • Fully converted all of K2M’s 1st-gen products to 2nd-gen under license agreement in Europe
  • Initiated U.S. randomized perspective clinical trial to compare 2nd-gen cervical SiN devices to PEEK
  • 88% enrolled in SNAP perspective study, comparing 1st-gen oblique lumbar SiN devices to PEEK interbody devices
  • Added 34 new surgeon customers YTD (12 in 1Q, 22 in 2Q)
  • 63 independent distributors to date, 250 sales reps